These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 25595669

  • 1. Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Manabe S, Shiragami C, Hirooka K, Izumibata S, Tsujikawa A, Shiraga F.
    Am J Ophthalmol; 2015 Apr; 159(4):644-51. PubMed ID: 25595669
    [Abstract] [Full Text] [Related]

  • 2. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy.
    Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N.
    Ophthalmology; 2012 Aug; 119(8):1666-78. PubMed ID: 22521082
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF.
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [Abstract] [Full Text] [Related]

  • 5. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [Abstract] [Full Text] [Related]

  • 6. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S.
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [Abstract] [Full Text] [Related]

  • 7. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
    Kim YK, Ryoo NK, Woo SJ, Park KH.
    Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
    [Abstract] [Full Text] [Related]

  • 8. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
    [Abstract] [Full Text] [Related]

  • 9. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy.
    Munk MR, Shah R, Pappas F, Baddar D, Wong B, Jampol LM, Fawzi AA.
    Curr Eye Res; 2016 Nov; 41(1):97-106. PubMed ID: 25612245
    [Abstract] [Full Text] [Related]

  • 10. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy.
    Hamzah F, Shinojima A, Mori R, Yuzawa M.
    BMC Ophthalmol; 2014 Nov 25; 14():145. PubMed ID: 25421855
    [Abstract] [Full Text] [Related]

  • 11. Choroidal thickness in central serous chorioretinopathy.
    Kuroda S, Ikuno Y, Yasuno Y, Nakai K, Usui S, Sawa M, Tsujikawa M, Gomi F, Nishida K.
    Retina; 2013 Feb 25; 33(2):302-8. PubMed ID: 23064424
    [Abstract] [Full Text] [Related]

  • 12. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb 25; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 13. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
    Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F.
    Am J Ophthalmol; 2010 Feb 25; 149(2):307-315.e2. PubMed ID: 19896635
    [Abstract] [Full Text] [Related]

  • 14. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
    Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T.
    Retina; 2011 Oct 25; 31(9):1921-7. PubMed ID: 21878850
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy.
    Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T.
    Retina; 2011 Sep 25; 31(8):1603-8. PubMed ID: 21487334
    [Abstract] [Full Text] [Related]

  • 17. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F.
    Am J Ophthalmol; 2014 May 25; 157(5):1033-7. PubMed ID: 24487046
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Focal choroidal excavation in eyes with central serous chorioretinopathy.
    Ellabban AA, Tsujikawa A, Ooto S, Yamashiro K, Oishi A, Nakata I, Miyake M, Akagi-Kurashige Y, Ueda-Arakawa N, Arichika S, Yoshitake S, Takahashi A, Yoshimura N.
    Am J Ophthalmol; 2013 Oct 25; 156(4):673-83. PubMed ID: 23831223
    [Abstract] [Full Text] [Related]

  • 20. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy.
    Okamoto M, Matsuura T, Ogata N.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan 25; 46(1):25-32. PubMed ID: 25559505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.